|
|
|
|
|
|
|
|
|
|
|
|
|
13.08.26 - 22:30
|
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights (Business Wire)
|
|
|
Commercial Momentum Builds Following CPT Code Implementation
Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing
CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT
Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets
Company Remains Focused on Delivering Strong Second Half PerformanceBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026.
Highlights included:
Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of units sold in the 2026 quarter, resulting in part from the inability to rec...
|
|
|
|
|
|
|
23.04.26 - 23:57
|
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026 (Business Wire)
|
|
|
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.
Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.
The call will be webcast live and can be accessed at this link or in the Invest...
|
|
|
|
|
18.02.26 - 14:33
|
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology (Business Wire)
|
|
|
New financing program provides a “one-stop” pathway for practices to acquire systems through outright purchase or several attractive leasing alternatives
Supports improved conversion of late-stage prospects as reimbursement clarity accelerates purchase decisions and lowers breakeven point to only one patient per monthBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structures.
Sensus Healthcare Financial Services is intended to support the acquisition of Sensus' full line of SRT and IG-SRT systems through customer-friendly financing structures and terms. The Company ...
|
|
|
|
|
|
|
|
|
12.02.26 - 22:09
|
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer (Business Wire)
|
|
|
2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026
Company enters 2026 with reimbursement certainty and strategic visibility, expects sequential-quarter revenue growth in Q1 and full-year profitability
Shipped 14 SRT systems in Q4, most in December and none to its historically largest customer, up from six systems in Q3 excluding shipments to its historically largest customer
Conference call begins at 4:30 p.m. Eastern time todayBOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025.
Highlights include the following:
Revenues were $4.9 million for the quarter and $27.5 million for the year
Net loss was $3.2 million for the quarter and $7.7 million ...
|
|
|
05.02.26 - 14:03
|
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026 (Business Wire)
|
|
|
BOCA RATON, Fla.--(BUSINESS WIRE)--$SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.
The call will be webcast live and...
|
|
|
07.01.26 - 14:36
|
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors (Business Wire)
|
|
|
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors.
Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologies. He currently serves as President, Imaging for the U.S. and Canada at GE HealthCare, where he is responsible for the company's largest global product and solutions segment. His prior work history includes positions with Elekta, Varian Medical Systems, Toshiba Medical, SMV Nuclear Me...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
